Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
Journal of Neuro-Oncology|February 18, 2015
Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experienceTony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.
Annals of Clinical and Translational Neurology|April 16, 2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastomaThomas J Kaley, Katherine S Panageas, Elena I Pentsova, et al.
Neuro-Oncology|April 12, 2020
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 PandemicNimish A Mohile, Jaishri O Blakeley, Na Tosha N Gatson, et al.
Nature Reviews. Clinical Oncology|April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumoursMaximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
Neuro-Oncology|March 12, 2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Neurosurgery|April 2, 2015
The Energy Index Does Not Affect Local Control of Brain Metastases Treated by Gamma Knife Stereotactic RadiosurgeryAshish Jani, Tzlil Rozenblat, Andrew M Yaeh, et al.
Neuro-Oncology Advances|September 22, 2021
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotinHui K Gan, Sagun Parakh, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
Journal of Neuro-Oncology|February 18, 2015
Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experienceTony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.
Annals of Clinical and Translational Neurology|April 16, 2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastomaThomas J Kaley, Katherine S Panageas, Elena I Pentsova, et al.
Neuro-Oncology|April 12, 2020
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 PandemicNimish A Mohile, Jaishri O Blakeley, Na Tosha N Gatson, et al.
Nature Reviews. Clinical Oncology|April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumoursMaximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
Neuro-Oncology|March 12, 2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Neurosurgery|April 2, 2015
The Energy Index Does Not Affect Local Control of Brain Metastases Treated by Gamma Knife Stereotactic RadiosurgeryAshish Jani, Tzlil Rozenblat, Andrew M Yaeh, et al.
Neuro-Oncology Advances|September 22, 2021
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotinHui K Gan, Sagun Parakh, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
Pageof 15